{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T20:58:00Z","timestamp":1790024280538,"version":"4.0.1"},"reference-count":27,"publisher":"American Society of Clinical Oncology (ASCO)","issue":"16","content-domain":{"domain":["ascopubs.org"],"crossmark-restriction":true},"short-container-title":["J Clin Oncol"],"published-print":{"date-parts":[[2026,6,1]]},"abstract":"<jats:sec>\n                    <jats:title>PURPOSE<\/jats:title>\n                    <jats:p>Chronic graft-versus-host disease (cGVHD) is a multisystem alloimmune disorder associated with abnormal B-cell biology and aberrant antibody responses. As B-cell\u2013directed therapy can effectively treat established cGVHD, we tested whether prophylactic B-cell depletion could prevent the development of corticosteroid-requiring cGVHD following allogeneic transplantation.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>METHODS<\/jats:title>\n                    <jats:p>We performed a randomized, placebo-controlled, and blinded trial comparing four doses of the B-cell\u2013depleting antibody obinutuzumab (1,000 mg once on days 90, 180, 270, and 365 after transplantation) with placebo in transplant recipients receiving tacrolimus-based GVHD prevention at higher risk of cGVHD. The primary end point was the 1-year incidence of corticosteroid-requiring cGVHD. We measured antibody responses against Y chromosome\u2013encoded minor histocompatibility (H-Y) antigens and correlated their occurrence with corticosteroid-requiring cGVHD incidence.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>RESULTS<\/jats:title>\n                    <jats:p>\n                      One hundred seventy-eight participants were analyzed. The prophylactic administration of obinutuzumab resulted in profound B-cell depletion, a significant reduction in the incidence of steroid-requiring cGVHD at 1 year (13.3%\n                      <jats:italic toggle=\"yes\">v<\/jats:italic>\n                      35.2%;\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = .0005), and an improvement in immunosuppression-free, relapse-free survival (48%\n                      <jats:italic toggle=\"yes\">v<\/jats:italic>\n                      34% at 2 years;\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = .02). Neutropenia was more common in the obinutuzumab arm, but nonrelapse mortality was not different. In participants without preformed H-Y antibodies at the time of study intervention, obinutuzumab resulted in the most significant reduction in steroid-requiring cGVHD at 12 months (8.6%) compared with obinutuzumab participants with H-Y antibodies (40%) or placebo participants regardless of antibody status (41% with antibodies, 57% without antibodies).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>CONCLUSION<\/jats:title>\n                    <jats:p>In allogeneic transplant recipients at higher risk of cGVHD, early B-cell depletion results in a significant reduction in the incidence of corticosteroid-requiring cGVHD.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1200\/jco-25-03104","type":"journal-article","created":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T19:59:07Z","timestamp":1777579147000},"page":"1529-1539","update-policy":"https:\/\/doi.org\/10.1200\/crossmark","source":"Crossref","is-referenced-by-count":2,"title":["Randomized, Placebo-Controlled Trial of B-Cell Depletion for Prevention of Corticosteroid-Requiring Chronic Graft-Versus-Host Disease"],"prefix":"10.1200","volume":"44","clinical-trial-number":[{"clinical-trial-number":"nct02867384","registry":"10.18810\/clinical-trials-gov"}],"author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8728-4314","authenticated-orcid":false,"given":"Corey","family":"Cutler","sequence":"first","affiliation":[{"name":"Division of Transplantation and Cellular Therapy, Dana-Farber Cancer Institute, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4889-6849","authenticated-orcid":false,"given":"Haesook T.","family":"Kim","sequence":"additional","affiliation":[{"name":"Department of Data Science, Dana-Farber Cancer Institute, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hassan","family":"El Banna","sequence":"additional","affiliation":[{"name":"Division of Transplantation and Cellular Therapy, Dana-Farber Cancer Institute, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth","family":"Halloran","sequence":"additional","affiliation":[{"name":"Division of Transplantation and Cellular Therapy, Dana-Farber Cancer Institute, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emily","family":"Matozel","sequence":"additional","affiliation":[{"name":"Division of Transplantation and Cellular Therapy, Dana-Farber Cancer Institute, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6839-3996","authenticated-orcid":false,"given":"Vincent T.","family":"Ho","sequence":"additional","affiliation":[{"name":"Division of Transplantation and Cellular Therapy, Dana-Farber Cancer Institute, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Koreth","sequence":"additional","affiliation":[{"name":"Division of Transplantation and Cellular Therapy, Dana-Farber Cancer Institute, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mahasweta","family":"Gooptu","sequence":"additional","affiliation":[{"name":"Division of Transplantation and Cellular Therapy, Dana-Farber Cancer Institute, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roman","family":"Shapiro","sequence":"additional","affiliation":[{"name":"Division of Transplantation and Cellular Therapy, Dana-Farber Cancer Institute, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7627-8509","authenticated-orcid":false,"given":"Amar","family":"Kelkar","sequence":"additional","affiliation":[{"name":"Division of Transplantation and Cellular Therapy, Dana-Farber Cancer Institute, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3700-5310","authenticated-orcid":false,"given":"Christopher","family":"Gibson","sequence":"additional","affiliation":[{"name":"Division of Transplantation and Cellular Therapy, Dana-Farber Cancer Institute, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-2711-5575","authenticated-orcid":false,"given":"Sarah","family":"Nikiforow","sequence":"additional","affiliation":[{"name":"Division of Transplantation and Cellular Therapy, Dana-Farber Cancer Institute, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Prashant","family":"Nageshwar","sequence":"additional","affiliation":[{"name":"Division of Transplantation and Cellular Therapy, Dana-Farber Cancer Institute, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carol","family":"Reynolds","sequence":"additional","affiliation":[{"name":"Division of Transplantation and Cellular Therapy, Dana-Farber Cancer Institute, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3424-915X","authenticated-orcid":false,"given":"Michela","family":"Ansuinelli","sequence":"additional","affiliation":[{"name":"Division of Transplantation and Cellular Therapy, Dana-Farber Cancer Institute, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-7188-0144","authenticated-orcid":false,"given":"Rakuyo","family":"Tamada","sequence":"additional","affiliation":[{"name":"Division of Transplantation and Cellular Therapy, Dana-Farber Cancer Institute, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-5448-166X","authenticated-orcid":false,"given":"Chloe","family":"Au","sequence":"additional","affiliation":[{"name":"Division of Transplantation and Cellular Therapy, Dana-Farber Cancer Institute, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-7430-1399","authenticated-orcid":false,"given":"Kevin","family":"Panaro","sequence":"additional","affiliation":[{"name":"Division of Transplantation and Cellular Therapy, Dana-Farber Cancer Institute, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-0695-5931","authenticated-orcid":false,"given":"Casey","family":"Gervais","sequence":"additional","affiliation":[{"name":"Division of Transplantation and Cellular Therapy, Dana-Farber Cancer Institute, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7994-8974","authenticated-orcid":false,"given":"Zachariah","family":"DeFilipp","sequence":"additional","affiliation":[{"name":"Hematopoietic Cell Transplant and Cell Therapy Program, Massachusetts General Hospital, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3556-1495","authenticated-orcid":false,"given":"Areej","family":"El-Jawahri","sequence":"additional","affiliation":[{"name":"Hematopoietic Cell Transplant and Cell Therapy Program, Massachusetts General Hospital, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9554-1058","authenticated-orcid":false,"given":"Yi-Bin","family":"Chen","sequence":"additional","affiliation":[{"name":"Hematopoietic Cell Transplant and Cell Therapy Program, Massachusetts General Hospital, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9268-9655","authenticated-orcid":false,"given":"Najla","family":"El Jurdi","sequence":"additional","affiliation":[{"name":"Division of Hematology, Oncology and Transplantation, University of Minnesota, Minneapolis, MN"},{"name":"Immune Deficiency Cellular Therapy Program, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8078-8579","authenticated-orcid":false,"given":"Daniel","family":"Weisdorf","sequence":"additional","affiliation":[{"name":"Division of Hematology, Oncology and Transplantation, University of Minnesota, Minneapolis, MN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Couriel","sequence":"additional","affiliation":[{"name":"Division of Hematology and Hematologic Malignancies, University of Utah, Salt Lake City, UT"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine","family":"Lee","sequence":"additional","affiliation":[{"name":"Division of Hematology and Hematologic Malignancies, University of Utah, Salt Lake City, UT"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sally","family":"Arai","sequence":"additional","affiliation":[{"name":"BMT and Cell Therapy Program, Stanford University, Palo Alto, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bita","family":"Sahaf","sequence":"additional","affiliation":[{"name":"BMT and Cell Therapy Program, Stanford University, Palo Alto, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juliana","family":"Bacigalupi","sequence":"additional","affiliation":[{"name":"BMT and Cell Therapy Program, Stanford University, Palo Alto, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathleen","family":"Ji","sequence":"additional","affiliation":[{"name":"BMT and Cell Therapy Program, Stanford University, Palo Alto, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5810-1192","authenticated-orcid":false,"given":"Robert","family":"Soiffer","sequence":"additional","affiliation":[{"name":"Division of Transplantation and Cellular Therapy, Dana-Farber Cancer Institute, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0717-4305","authenticated-orcid":false,"given":"David","family":"Miklos","sequence":"additional","affiliation":[{"name":"BMT and Cell Therapy Program, Stanford University, Palo Alto, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph H.","family":"Antin","sequence":"additional","affiliation":[{"name":"Division of Transplantation and Cellular Therapy, Dana-Farber Cancer Institute, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5526-4669","authenticated-orcid":false,"given":"Jerome","family":"Ritz","sequence":"additional","affiliation":[{"name":"Division of Transplantation and Cellular Therapy, Dana-Farber Cancer Institute, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"233","reference":[{"key":"e_1_3_9_2_2","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.27597"},{"key":"e_1_3_9_3_2","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2017014977"},{"key":"e_1_3_9_4_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2008-10-161638"},{"key":"e_1_3_9_5_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-08-801001"},{"key":"e_1_3_9_6_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2004-09-3660"},{"key":"e_1_3_9_7_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-03-562231"},{"key":"e_1_3_9_8_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2006-01-0233"},{"key":"e_1_3_9_9_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2009.04.003"},{"key":"e_1_3_9_10_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-07-793786"},{"key":"e_1_3_9_11_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-04-495895"},{"key":"e_1_3_9_12_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-12-395970"},{"key":"e_1_3_9_13_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.isci.2021.102089"},{"key":"e_1_3_9_14_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41573-020-00092-2"},{"key":"e_1_3_9_15_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2014.12.001"},{"key":"e_1_3_9_16_2","doi-asserted-by":"publisher","DOI":"10.1007\/978-1-61779-043-0_7"},{"key":"e_1_3_9_17_2","first-page":"289","article-title":"Requirement for B cells in T cell priming to minor histocompatibility antigens and development of graft-versus-host disease","volume":"16","author":"Schultz KR","year":"1995","unstructured":"Schultz KR, Paquet J, Bader S, et al: Requirement for B cells in T cell priming to minor histocompatibility antigens and development of graft-versus-host disease. Bone Marrow Transpl 16:289-295, 1995","journal-title":"Bone Marrow Transpl"},{"key":"e_1_3_9_18_2","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20031560"},{"key":"e_1_3_9_19_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-11-784017"},{"key":"e_1_3_9_20_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2003-03-0984"},{"key":"e_1_3_9_21_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-11-613323"},{"key":"e_1_3_9_22_2","first-page":"179.e1","article-title":"A phase I trial of SYK inhibition with fostamatinib in the prevention and treatment of chronic graft-versus-host disease","volume":"29","author":"Lin C","year":"2023","unstructured":"Lin C, DiCioccio RA, Haykal T, et al: A phase I trial of SYK inhibition with fostamatinib in the prevention and treatment of chronic graft-versus-host disease. Transpl Cell Ther 29:179.e1-179.e10, 2023","journal-title":"Transpl Cell Ther"},{"key":"e_1_3_9_23_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.22.00509"},{"key":"e_1_3_9_24_2","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2017.176859"},{"key":"e_1_3_9_25_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2015.03.014"},{"key":"e_1_3_9_26_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41409-018-0399-7"},{"key":"e_1_3_9_27_2","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2015.1016707"},{"key":"e_1_3_9_28_2","doi-asserted-by":"publisher","DOI":"10.1093\/jimmun\/vkaf008"}],"container-title":["Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ascopubs.org\/doi\/pdfdirect\/10.1200\/JCO-25-03104","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,27]],"date-time":"2026-05-27T21:59:17Z","timestamp":1779919157000},"score":1,"resource":{"primary":{"URL":"https:\/\/ascopubs.org\/doi\/10.1200\/JCO-25-03104"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,1]]},"references-count":27,"journal-issue":{"issue":"16","published-print":{"date-parts":[[2026,6,1]]}},"alternative-id":["10.1200\/JCO-25-03104"],"URL":"https:\/\/doi.org\/10.1200\/jco-25-03104","relation":{},"ISSN":["0732-183X","1527-7755"],"issn-type":[{"value":"0732-183X","type":"print"},{"value":"1527-7755","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,1]]},"assertion":[{"value":"2025-12-25","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-01-24","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-03-16","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-04-30","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}